Inhalation delivery systems with compliance and disease management capabilities

Area of Science:

• Pulmonary Drug Delivery
• Biomedical Engineering
• Pharmacology

Background:

• Medication non-compliance significantly impacts therapeutic outcomes and increases healthcare expenses.
• Poor technique in self-administration of inhalation therapy is a specific challenge in pulmonary drug delivery.
• Pulmonary drug delivery offers site-directed advantages for respiratory tract diseases and systemic circulation access.

Purpose of the Study:

• To explore the role of microprocessor-assisted pulmonary drug delivery systems in managing chronic respiratory diseases.
• To highlight the capabilities of advanced devices in improving patient compliance and drug deposition.
• To present novel technologies for enhanced drug and diagnostic agent delivery via inhalation.

Main Methods:

• Review of microprocessor integration into pulmonary drug delivery systems.
• Description of SmartMist device for asthma management, including lung function measurement.
• Explanation of the AERx system's novel aqueous aerosol generation from unit dose packages.

Main Results:

• Microprocessor-assisted systems enable control over patient inhalation technique, ensuring efficient and reproducible drug deposition.
• SmartMist provides optimal metered-dose inhaler use, lung function monitoring, and electronic record-keeping.
• The AERx system offers a versatile platform for delivering various agents to the respiratory tract and systemically.

Conclusions:

• Microprocessor-enhanced pulmonary drug delivery systems are crucial for sophisticated compliance management in chronic diseases like asthma.
• These technologies improve the efficacy of inhaled therapies through precise administration and monitoring.
• Advanced systems like SmartMist and AERx represent significant advancements in respiratory and systemic drug delivery.